Obecure Achieves Successful Results in Its Proof of Concept Clinical Study Evaluating the Ability of Histalean(TM) to Mitigate Weight Gain Associated With Olanzapine

RAMAT GAN, Israel--(BUSINESS WIRE)--Obecure Ltd., a subsidiary of Bio-Light Israeli Life Science Investments Ltd. (TASE:BOLT), announces a positive outcome of its BET-209 clinical study, a randomized, double-blinded, placebo-controlled, four week Phase Ib, Proof-of-Concept (POC) study evaluating both the safety and the ability of HistaleanTM to mitigate the weight gain side effect associated with the anti psychotic drug, Olanzapine.